Preparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinoma-targeted drug delivery

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1207-1222

  Zu, Yuangang ^a   Meng, Li ^a   Zhao, Xiuhua ^a   Ge, Yunlong ^a   Yu, Xinyang ^a   Zhang, Yin ^a   Deng, Yiping ^a  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

BSA; GL; HCPT; High pressure homogenization emulsification

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BOVINE SERUM ALBUMIN; FLUORESCEIN ISOTHIOCYANATE; GLYCYRRHIZIC ACID; NANOPARTICLE;

ARTICLE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG ENCAPSULATION EFFICIENCY; DRUG LOADING EFFICIENCY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE; HEMOLYSIS; HOMOGENIZATION PRESSURE; HOMOGENIZATION SPEED DURATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIVER CELL CARCINOMA; MAXIMAL INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHARMACEUTICS; PHYSICAL PARAMETERS; RABBIT; THERMAL ANALYSIS; THERMOSTABILITY; WATER VOLUME RATIO TO ORGANIC PHASE; X RAY DIFFRACTION; ZETA POTENTIAL;

BSA; GL; HCPT; HIGH-PRESSURE HOMOGENIZATION EMULSIFICATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CATTLE; CELL LINE, TUMOR; DRUG CARRIERS; GLYCYRRHIZIC ACID; HEMOLYSIS; HUMANS; LIVER NEOPLASMS; NANOPARTICLES; PARTICLE SIZE; RABBITS; SERUM ALBUMIN, BOVINE;

BOVINAE;

EID: 84875673833     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40493     Document Type: Article

References (48)

1. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989;49(6):1465-1469.
2. Wang J, Wang R, Li LB. Preparation and properties of hydroxycamptothecin-loaded nanoparticles made of amphiphilic copolymer and normal polymer. J Colloid Interface Sci. 2009;336(2):808-813.
3. Pu X, Sun J, Wang Y, etal. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm. 2009;379(1): 167-173.
4. Zhang C, Ding Y, Yu LL, Ping Q. Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives. Colloids Surf B Biointerfaces. 2007;55(2):192-199.
5. Widlak P, Li LY, Wang X, Garrard WT. Action of recombinant human apoptotic endonuclease G on naked DNA and chromatin substrates: cooperation with exonuclease and DNase I. J Biol Chem. 2001;276(51):48404-48409.
6. Fu YR, Yi ZJ, Yan YR, Qiu ZY. Hydroxycamptothecin-induced apoptosis in hepatoma SMMC-7721cells and the role of mitochondrial pathway. Mitochondrion. 2006;6(4):211-217.
7. Sheth P, Sandhu H, Singhal D, Malick W, Shah N, Kislalioglu MS. Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production. Curr Drug Deliv. 2012;9(3):269-284.
8. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer. 1998;34(10):1500-1508.
9. Zhao X, Jiang R, Zu Y, etal. Process optimization studies of 10-Hydroxycamptothecin (HCPT)-loaded folate-conjugated chitosan nanoparticles by SAS-ionic crosslink combination using response surface methodology (RSM). Appl Surf Sci. 2012;258(6):2000-2005.
10. Wei W, Yue ZG, Qu JB, Yue H, Su ZG, Ma GH. Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation. Nanomedicine (Lond). 2010;5(4):589-596.
11. Hong M, Zhu S, Jiang Y, Tang G, Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release. 2009;133(2):96-102.
12. Yang X, Li L, Wang Y, Tan Y. Preparation, pharmacokinetics and tissue distribution of micelles made of reverse thermo-responsive polymers. Int J Pharm. 2009;370(1-2):210-215.
13. Min KH, Park K, Kim YS, etal. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release. 2008;127(3):208-218.
14. Bokharaei M, Margaritis A, Xenocostas A, Freeman DJ. Erythropoietin encapsulation in chitosan nanoparticles and kinetics of drug release. Curr Drug Deliv. 2011;8(2):164-171.
15. Mehta AK, Yadav KS, Sawant KK. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv. 2007;4(3):185-193.
16. Sun X, Wu F, Lu W, Zhang ZR. Sustained-release hydroxycamptothecin polybutylcyanoacrylate nanoparticles as a liver targeting drug delivery system. Pharmazie. 2004;59(10):791-794.
17. Li Q, Liu C, Zhao X, etal. Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. Int J Nanomedicine. 2011;6:397-405.
18. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157(2):168-182.
19. Hu YJ, Liu Y, Sun TQ, Bai AM, Lü JQ, Pi ZB. Binding of anti-inflammatory drug cromolyn sodium to bovine serum albumin. Int J Biol Macromol. 2006;39(4-5):280-285.
20. Tantra R, Tompkins J, Quincey P. Characterisation of the de-agglomeration effects of bovine serum albumin on nanoparticles in aqueous suspension. Colloids Surf B Biointerfaces. 2010;75(1):275-281.
21. Yang L, Cui F, Cun D, Tao A, Shi K, Lin W. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int J Pharm. 2007;340(1-2):163-172.
22. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res. 2004;21(11):2001-2008.
23. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-156.
24. Lambert B, Bacher K, Defreyne L, etal. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med. 2005;46(1):60-66.
25. Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med Biol. 2008;35(5):589-597.
26. Law AL, Ng WT, Lee MC, etal. Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control. Radiother Oncol. 2012;102(1):56-61.
27. Nowak AK, Chow PKH, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40(10):1474-1484.
28. Tripathi M, Singh BK, Kakkar P. Glycyrrhizic acid modulates t-BHP induced apoptosis in primary rat hepatocytes. Food Chem Toxicol. 2009;47(2):339-347.
29. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol. 1999;14(11):1093-1099.
30. Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, DeJongh J. The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev. 2001;33(2): 125-147.
31. Tsuji H, Osaka S, Kiwada H. Targeting of liposomes surface-modified with glycyrrhizin to the liver. I. Preparation and biological disposition. Chem Pharm Bull (Tokyo). 1991;39(4):1004-1008.
32. Osaka S, Tsuji H, Kiwada H. Uptake of liposomes surface-modified with glycyrrhizin by primary cultured rat hepatocytes. Biol Pharm Bull. 1994;17(7):940-943.
33. Lin A, Chen J, Liu Y, etal. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm. 2009;35(11):1348-1355.
34. Mao S, Hou S, Zhang L, etal. Preparation of valaciclovir loaded bovine serum albumin nanoparticles surface-modified with glycyrrhizin and its characteristics of targeting to liver. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004;21(4):570-574. Chinese.
35. Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. National Institutes of Health Publication No 85-23. Washington DC: National Academies Press; 1996.
36. Zhang L, Sun Y, Chen T, Xu Q. Selective depletion of glycyrrhizin from Si-Ni-San, a traditional Chinese prescription, blocks its effect on contact sensitivity in mice and recovers adhesion and metalloproteinases production of T lymphocytes. Int Immunopharmacol. 2005;5(7-8):1193-1204.
37. Zu Y, Zhang Y, Zhao X, Zhang Q, Liu Y, Jiang R. Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM). Int J Nanomedicine. 2009;4:321-333.
38. Lian H, Sun J, Yu YP, etal. Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery. Int J Nanomedicine. 2011;6:3323-3334.
39. Sun JB, Duan JH, Dai SL, etal. In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers. Cancer Lett. 2007;258(1):109-117.
40. Tcholakova S, Denkov ND, Ivanov IB, Campbell B. Coalescence stability of emulsions containing globular milk proteins. Adv Colloid Interface Sci. 2006;123-126:259-293.
41. Affandi MMM, Julianto T, Majeed A. Development and stability evaluation of astaxanthin nanoemulsion. Asian J Pharm Clin Res. 2011;4:142-148.
42. Obolentseva GV, Litvinenko VI, Ammosov AS, Popova TP, Sampiev AM. Pharmacological and therapeutic properties of licorice preparations (A review). Pharm Chem J. 1999;33(8):427-434.
43. Obolentseva GV, Litvinenko VI, Ammosov AS, Popova TP, Sampiev AM. Pharmacological and therapeutic properties of licorice preparations (A review). Pharmaceutical Chemistry Journal. 1999; 33(8):427-434.
44. Zhao X, Zu Y, Zu S, Wang D, Zhang Y, Zu B. Insulin nanoparticles for transdermal delivery: preparation and physicochemical characterization and in vitro evaluation. Drug Dev Ind Pharm. 2010; 36(10):1177-1185.
45. Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm. 2008; 359(1-2):211-219.
46. Grinberg O, Gedanken A, Patra CR, Patra S, Mukherjee P, Mukhopadhyay D. Sonochemically prepared BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics. Acta Biomater. 2009;5(8):3031-3037.
47. Peng YR, Li YB, Liu XD, Zhang JF, Duan JA. Apoptosis induced by caudatin in human hepatoma cell line SMMC7721. Chin J Nat Med. 2008;6(3):210-213.
48. Stockert JC, Blázquez-Castro A, Cañete M, Horobin RW, Villanueva Á. MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta Histochem. 2012;114(8):785-796.